BiotechTube

ASP0892 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Mar 12, 2019 → Oct 11, 2021

NCT ID
NCT03755713

About ASP0892 + Placebo

ASP0892 + Placebo is a phase 1 stage product being developed by Astellas Pharma for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03755713. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03755713Phase 1Completed

Competing Products

20 competing products in Peanut Allergy

See all competitors
ProductCompanyStageHype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo IntramuscularAstellas PharmaPhase 1
33
ligelizumab + PlaceboNovartisPhase 3
77
remibrutinib + placeboNovartisPhase 2
52
QGE031 + PlaceboNovartisPhase 2
52
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
77
Dupilumab + Placebo matching dupilumab + AR101SanofiPhase 2
51
DupilumabSanofiPhase 2
51
Etokimab + PlaceboAnaptysBioPhase 2
47
DBV712 IHRPDBV TechnologiesPhase 1
28
Epicutaneous Immunotherapy + placebo of peanutDBV TechnologiesPhase 2
47
Viaskin Peanut 250 mcg + PlaceboDBV TechnologiesPhase 3
72
Viaskin PeanutDBV TechnologiesPre-clinical
18
Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin PlaceboDBV TechnologiesPhase 2
47
DBV712 250 mcgDBV TechnologiesPhase 3
72
Whole peanut extract + Placebo formulationDBV TechnologiesPhase 1
28
Viaskin Peanut 250 mcgDBV TechnologiesPhase 2
47
DBV712 + DBV712DBV TechnologiesPhase 3
72
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboDBV TechnologiesPhase 3
72
Viaskin Peanut 250mcg + PlaceboDBV TechnologiesPhase 3
72
Viaskin Peanut 250µgDBV TechnologiesPhase 3
72

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85